Vaginal microbicides and their delivery platforms

Bibliography

• Global report: UNAIDS report on the global AIDS epidemic 2013. Available from: http://www.unaids.org/en/resources/campaigns/globalreport2013/
   Google Scholar
• Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008;8:447-57
   PubMed Web of Science ®Google Scholar
• Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011;62:127-39
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004;10:315-36
   PubMed Web of Science ®Google Scholar
• Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998;339:504-10
   PubMed Web of Science ®Google Scholar
• Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo controlled trial in ghana. PLoS One 2007;2:e1312
   PubMed Web of Science ®Google Scholar
• Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474
   PubMed Web of Science ®Google Scholar
• Van Damme L, Govinden R, Mirembe F, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-72
   PubMed Web of Science ®Google Scholar
• Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-87
   PubMed Web of Science ®Google Scholar
• Abdool Karim S, Coletti A, Richardson B, et al. HIV prevention trials network (HPTN) 035 study team. safety and effectiveness of vaginal microbicides Buffer Gel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. AIDS 2011;25:957-66
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Recent advances in anogenital antiretroviral microbicides and multimodal delivery systems. J AIDS Clinic Res 2012;3:144
   Google Scholar
• Klasse PJ, Shattock R, Moore JP. Antiretroviral drug based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008;59:455-71
   PubMed Web of Science ®Google Scholar
• Carias AM, McCoombe S, McRaven M, et al. Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J Virol 2013;87:11388-400
   PubMed Web of Science ®Google Scholar
• Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008;319:921-6
   PubMed Web of Science ®Google Scholar
• Zhou H, Xu M, Huang Q, et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008;4:495-504
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Enzyme Inhib Med Chem 2006;21:329-50
   PubMed Web of Science ®Google Scholar
• Acartürk F. Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul 2009;3:193-205
   PubMedGoogle Scholar
• Grabovac V, Guggi D, Bernkop-Schnürch A. Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev 2005;57:1713-23
   PubMed Web of Science ®Google Scholar
• Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006;194:904-11
   PubMed Web of Science ®Google Scholar
• García-Lerma JG, Heneine W. Animal models of antiretroviral prophylaxis for HIV prevention. Curr Opin HIV AIDS 2012;7:505-13
   PubMedGoogle Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74
   PubMed Web of Science ®Google Scholar
• VOICE HIV prevention trial discontinues Tenofovir gel arm. Available from: http://www.fhi360.org/en/AboutFHI/Media/Releases/VOICE_discontinues_tenofovir_gel112511.htm [Last updated 25 November 2011]
   Google Scholar
• Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009;89:513-19
   PubMed Web of Science ®Google Scholar
• Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a crosssectional study. J Infect Dis 2009;200:1746-54
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011;91:852-8
   PubMed Web of Science ®Google Scholar
• White KL, Chen JM, Margot NA, et al. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 2004;48:992-1003
   PubMed Web of Science ®Google Scholar
• Das K, Bandwar RP, White KL, et al. Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 2009;284:35092-100
   PubMed Web of Science ®Google Scholar
• Hachiya A, Kodama EN, Schuckmann MM, et al. K70Q adds high-level tenofovir resistance to “Q151M complex” HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One 2011;6:e16242
   PubMed Web of Science ®Google Scholar
• Cahn P, Rolon MJ, Gun AM, et al. Preclinical and first-in-human Phase I clinical evaluation of Stampidine, a potent anti-HIV pharmaceutical drug candidate. J AIDS Clinic Res 2012;3:138
   Google Scholar
• Uckun FM, Pendergrass S, Venkatachalam TK, et al. Stampidine is a potent inhibitor of zidovudine and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical HIV-1 isolates with thymidine analog mutations. Antimicrob Agents Chemother 2002;46:3613-16
   PubMed Web of Science ®Google Scholar
• Uckun FM, Pendergrass S, Qazi S, Venkatachalam TK. In vitro activity of stampidine against primary clinical HIV isolates. Arzneimittelforschung 2004;54:69-77
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S, Venkatachalam TK. In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung 2005;55:223-31
   PubMed Web of Science ®Google Scholar
• Uckun FM, Venkatachalam TK, Qazi S. Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. Arzneimittelforschung 2006;56:193-203
   PubMed Web of Science ®Google Scholar
• Uckun FM, DuMez D, Qazi S, et al. Antiretroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. Arzneimittelforschung 2007;57:112-21
   PubMed Web of Science ®Google Scholar
• Chen CL, Yu G, Venkatachalam T, Uckun FM. Metabolism of stavudine-5'-[p-bromophenyl methoxy alaninyl phosphate], stampidine, in mice, dogs, and cats. Drug Metab Dispos 2002;30:1523-31
   PubMed Web of Science ®Google Scholar
• Uckun FM, Waurzyniak B, Tibbles H, et al. In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats. Arzneimittelforschung 2006;56:176-92
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S, Pendergrass S, et al. In vivo toxicity, pharmacokinetics, and anti-HIV activity of stavudine-5'-(p-bromo phenyl methoxyalaninyl phosphate) (stampidine) in mice. Antimicrob Agents Chemother 2002;46:3428-36
   PubMed Web of Science ®Google Scholar
• Uckun FM, Chen CL, Samuel P, et al. In vivo antiretroviral activity of stampidine in chronically FIV-infected cats. Antimicrob Agents Chemother 2003;47:1233-40
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Fertil Steril 2004;81(Suppl 1):831-41
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S. Stampidine as a potent epigenetic silencer of host HIV dependency factor genes in HIV-infected cells. J AIDS Clinic Res 2012;4
   Google Scholar
• Fletcher P, Harman S, Azijn H, et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009;53:487-95
   PubMed Web of Science ®Google Scholar
• Nel AM, Coplan P, Smythe SC, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010;26:1181-90
   PubMed Web of Science ®Google Scholar
• Romano J, Variano B, Coplan P, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009;25:483-8
   PubMed Web of Science ®Google Scholar
• Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009;51:416-23
   PubMed Web of Science ®Google Scholar
• Schader SM, Oliveira M, Ibanescu RI, et al. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrob Agents Chemother 2011;56:751-6
   PubMed Web of Science ®Google Scholar
• Kenney J, Aravantinou M, Singer R, et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 2011;6:e15835
   PubMedGoogle Scholar
• Mao C, Sudbeck EA, Venkatachalam TK, et al. Structure-based drug design of nonnucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem Pharmacol 2000;60:1251-65
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S, Venkatachalam T. N'-[2-(2-thiophene) ethyl]-N'-[2-(5-bromopyridyl)] thiourea (HI-443), a rationally designed non-nucleoside reverse transcriptase inhibitor compound with potent anti-HIV activity. Arzneimittelforschung 2007;57:278-85
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Qazi S, Yiv S, Uckun FM. A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene) ethyl]-N'-[2-(5-bromopyridyl)] thiourea]). Expert Opin Investig Drugs 2012;21:265-79
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Samuel P, Uckun FM. PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biol Reprod 2004;71:2037-47
   PubMed Web of Science ®Google Scholar
• Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003;348:2228-38
   PubMed Web of Science ®Google Scholar
• Choe H, Farzan M, Sun Y, et al. The beta chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-48
   PubMed Web of Science ®Google Scholar
• Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996;381:661-6
   PubMed Web of Science ®Google Scholar
• Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV suppressive factors produced by CD8+ T cells. Science 1995;270:1811-15
   PubMed Web of Science ®Google Scholar
• Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004;306:485-7
   PubMed Web of Science ®Google Scholar
• Veazey RS, Ketas TJ, Dufour J, et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010;202:739-44
   PubMed Web of Science ®Google Scholar
• Vangelista L, Secchi M, Lusso P. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine 2008;26:3008-15
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466-70
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009;5:e1000433
   PubMed Web of Science ®Google Scholar
• Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75:8340-7
   PubMed Web of Science ®Google Scholar
• Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012;492:118-22
   PubMed Web of Science ®Google Scholar
• Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002;8:681-6
   PubMed Web of Science ®Google Scholar
• Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59:75-86
   PubMed Web of Science ®Google Scholar
• Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134:577-86
   PubMed Web of Science ®Google Scholar
• De Rosa G, La Rotonda MI. Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties. Molecules 2009;14:2801-23
   PubMed Web of Science ®Google Scholar
• Khati M, Schüman M, Ibrahim J, et al. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-NA aptamers. J Virol 2003;77:12692-8
   PubMed Web of Science ®Google Scholar
• McNamara JO II, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;8:1005-15
   Web of Science ®Google Scholar
• Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008;16:1481-9
   PubMed Web of Science ®Google Scholar
• Neff CP, Zhou J, Remling L, et al. An aptamer siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 2011;3:66ra6
   PubMed Web of Science ®Google Scholar
• Ham AS, Cost MR, Sassi AB, et al. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 2009;26:502-11
   PubMed Web of Science ®Google Scholar
• Bowman MC, Ballard TE, Ackerson CJ, et al. Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc 2008;130:6896-7
   PubMed Web of Science ®Google Scholar
• Bastian AR, Kantharaju McFadden K, et al. Cellfree HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120. ChemMedChem 2011;6:1335-9
   PubMed Web of Science ®Google Scholar
• Elechiguerra JL, Burt JL, Morones JR, et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 2005;3:6
   Google Scholar
• Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, et al. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 2010;8:1
   Google Scholar
• Lara HH, Ixtepan-Turrent L, Garza-Treviño EN, et al. PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology 2010;8:15
   PubMedGoogle Scholar
• Tyssen D, Henderson SA, Johnson A, et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One 2010;5:e12309
   Google Scholar
• Jiang YH, Emau P, Cairns JS, et al. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2005;21:207-13
   PubMed Web of Science ®Google Scholar
• Cohen CR, Brown J, Moscicki AB, et al. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days. PLoS One 2011;6:e16258
   Google Scholar
• Caron M, Besson G, Etenna SL-D, et al. Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus Macaques with RT-SHIV. Virology 2010;405:225-33
   PubMed Web of Science ®Google Scholar
• Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45:89-121
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Gel-microemulsions as vaginal spermicides and intravaginal drug delivery vehicles. Contraception 2001;64:113-23
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Yiv SH, Uckun FM. GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion. AAPS PharmSciTech 2001;2:E5
   PubMedGoogle Scholar
• D'Cruz OJ, Uckun FM. Pre-clinical safety evaluation of novel nucleoside analogue-based dual-function microbicides (WHI-05 and WHI-07). J Antimicrob Chemother 2002;50:793-803
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Samuel P, Uckun FM. Conceival, a novel non-contraceptive vaginal vehicle for lipophilic microbicides. AAPS PharmSciTech 2005;6:E56-64
   PubMedGoogle Scholar
• Malcolm K, Woolfson D, Russell J, et al. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release 2003;90:217-25
   PubMed Web of Science ®Google Scholar
• Malcolm RK, Edwards KL, Kiser P, et al. Advances in microbicide vaginal rings. Antiviral Res 2010;88:S30-9
   PubMed Web of Science ®Google Scholar
• Singer R, Mawson P, Derby N. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med 2012;4:150ra123
   PubMed Web of Science ®Google Scholar
• Teller RS, Srinivasan P, Mesquita PM, et al. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci USA 2013;110:16145-50
   PubMed Web of Science ®Google Scholar
• Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 1998;12:1699-706
   PubMed Web of Science ®Google Scholar
• Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008;6:349-62
   PubMed Web of Science ®Google Scholar
• Pusch O, Boden D, Hannify S, et al. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J Acquir Immune Defic Syndr 2005;40:512-20
   PubMed Web of Science ®Google Scholar
• Ying T, Chen W, Feng Y, et al. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem 2013;288:25154-64
   PubMed Web of Science ®Google Scholar